Compared to genetic engineering T cell technologies, which require complicated and long-term preparation processes, the BsAb-armed T cell technology provides an extremely simplified method for producing cancer-specific T cells with a purity of over 90%, with the process only requiring the co-culturing of PBMCs with anti-cancer/anti-CD3 (scFv-Fab) BsAb and IL-2 for 7 days. This evidence concerns the gene IL2 and cancer.